CervoMed Statistics
Total Valuation
CervoMed has a market cap or net worth of $65.42 million. The enterprise value is $31.89 million.
Important Dates
The next estimated earnings date is Tuesday, November 11, 2025, before market open.
| Earnings Date | Nov 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CervoMed has 9.25 million shares outstanding. The number of shares has increased by 43.26% in one year.
| Current Share Class | 9.25M |
| Shares Outstanding | 9.25M |
| Shares Change (YoY) | +43.26% |
| Shares Change (QoQ) | +2.85% |
| Owned by Insiders (%) | 31.44% |
| Owned by Institutions (%) | 14.34% |
| Float | 5.48M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.97 |
| Forward PS | 17.49 |
| PB Ratio | 1.96 |
| P/TBV Ratio | 1.96 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.10 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.20
| Current Ratio | 8.20 |
| Quick Ratio | 7.73 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -54.21% and return on invested capital (ROIC) is -36.80%.
| Return on Equity (ROE) | -54.21% |
| Return on Assets (ROA) | -33.63% |
| Return on Invested Capital (ROIC) | -36.80% |
| Return on Capital Employed (ROCE) | -73.43% |
| Revenue Per Employee | $518,465 |
| Profits Per Employee | -$1.51M |
| Employee Count | 15 |
| Asset Turnover | 0.17 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -42.89% in the last 52 weeks. The beta is -6.36, so CervoMed's price volatility has been lower than the market average.
| Beta (5Y) | -6.36 |
| 52-Week Price Change | -42.89% |
| 50-Day Moving Average | 8.66 |
| 200-Day Moving Average | 7.20 |
| Relative Strength Index (RSI) | 36.01 |
| Average Volume (20 Days) | 111,177 |
Short Selling Information
The latest short interest is 181,510, so 1.96% of the outstanding shares have been sold short.
| Short Interest | 181,510 |
| Short Previous Month | 192,726 |
| Short % of Shares Out | 1.96% |
| Short % of Float | 3.31% |
| Short Ratio (days to cover) | 1.73 |
Income Statement
In the last 12 months, CervoMed had revenue of $7.78 million and -$22.61 million in losses. Loss per share was -$2.58.
| Revenue | 7.78M |
| Gross Profit | -14.38M |
| Operating Income | -24.56M |
| Pretax Income | -22.61M |
| Net Income | -22.61M |
| EBITDA | n/a |
| EBIT | -24.56M |
| Loss Per Share | -$2.58 |
Full Income Statement Balance Sheet
The company has $33.53 million in cash and n/a in debt, giving a net cash position of $33.53 million or $3.62 per share.
| Cash & Cash Equivalents | 33.53M |
| Total Debt | n/a |
| Net Cash | 33.53M |
| Net Cash Per Share | $3.62 |
| Equity (Book Value) | 33.44M |
| Book Value Per Share | 3.61 |
| Working Capital | 33.44M |
Full Balance Sheet Cash Flow
| Operating Cash Flow | -23.31M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow Statement Margins
Gross margin is -184.92%, with operating and profit margins of -315.76% and -290.75%.
| Gross Margin | -184.92% |
| Operating Margin | -315.76% |
| Pretax Margin | -290.75% |
| Profit Margin | -290.75% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CervoMed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -43.26% |
| Shareholder Yield | -43.26% |
| Earnings Yield | -34.57% |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CervoMed is $19.17, which is 171.15% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $19.17 |
| Price Target Difference | 171.15% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 53.21% |
| EPS Growth Forecast (5Y) | -26.65% |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CervoMed has an Altman Z-Score of 6.39.
| Altman Z-Score | 6.39 |
| Piotroski F-Score | n/a |